Compare ULH & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | VNDA |
|---|---|---|
| Founded | 1932 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.8M | 361.4M |
| IPO Year | 2004 | 2005 |
| Metric | ULH | VNDA |
|---|---|---|
| Price | $19.24 | $4.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $20.00 | $14.90 |
| AVG Volume (30 Days) | 38.9K | ★ 976.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,461,708,000.00 | $216,105,000.00 |
| Revenue This Year | $2.73 | $21.35 |
| Revenue Next Year | $5.12 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $11.73 | $4.27 |
| 52 Week High | $27.20 | $9.91 |
| Indicator | ULH | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 33.49 |
| Support Level | $13.33 | N/A |
| Resistance Level | $23.49 | $5.46 |
| Average True Range (ATR) | 1.62 | 0.25 |
| MACD | 0.54 | -0.00 |
| Stochastic Oscillator | 85.63 | 45.03 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.